| NCT05671835 | Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis | COMPLETED | PHASE2 | 2023-05-15 | 2025-08-14 | 2025-08-14 |
| NCT05440708 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | RECRUITING | PHASE1, PHASE2 | 2023-03-23 | 2027-06-28 | 2026-06-29 |
| NCT05384119 | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer | TERMINATED | PHASE1 | 2023-01-09 | 2024-04-25 | 2024-04-25 |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers | COMPLETED | PHASE1 | 2017-11-15 | 2024-06-24 | 2024-06-24 |